Payment overview · 2025
General Payments
$2,429.41
136 reported records · 19 companies
Healthcare provider profile · identity verified
Jarred Jones, MD
Allopathic & Osteopathic Physicians|Family Medicine · LONDON, KY · NPI 1396374575
Verified facts
What the public records show
CMS Open Payments records show Jarred Jones, MD received $2,429.41 in general payments during 2025 across 136 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Mounjaro, Nurtec Odt, Ozempic, Synthroid, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $309.07 | 12.7% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $299.35 | 12.3% | 19 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $271.07 | 11.2% | 12 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $252.06 | 10.4% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $237.56 | 9.8% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.42 | 7.2% | 13 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $144.61 | 6.0% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $133.88 | 5.5% | 6 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $106.68 | 4.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $89.65 | 3.7% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $76.54 | 3.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $72.06 | 3.0% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $68.41 | 2.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $59.20 | 2.4% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.92 | 2.1% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.48 | 1.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.49 | 0.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.12 | 0.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $13.84 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,429.41 | 136 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $271.07 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $264.69 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $252.06 | 21 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $200.34 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $197.98 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $193.65 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $193.65 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $169.23 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $155.96 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $144.61 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $133.88 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.92 | 8 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $106.68 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $105.70 | 8 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $76.54 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $73.53 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $73.53 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $72.06 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $68.41 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $59.20 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.50 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.92 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.25 | 5 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $40.48 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.75 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 103 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 136 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 65 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
136 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 496 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 380 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 362 | 130 |
| Gabapentin | Gabapentin | 351 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 269 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 111 |
| Lisinopril | Lisinopril | 203 | 83 |
| Alprazolam | Alprazolam | 192 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 176 | 83 |
| Tramadol Hcl | Tramadol Hcl | 176 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 50 |
| Clonazepam | Clonazepam | 138 | 47 |
| Mounjaro | Tirzepatide | 136 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 44 |
| Metformin Hcl | Metformin Hcl | 118 | 53 |
| Prednisone | Prednisone | 114 | 71 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 112 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 41 |
| Ozempic | Semaglutide | 108 | 30 |
| Losartan Potassium | Losartan Potassium | 107 | 45 |
| Furosemide | Furosemide | 106 | 41 |
| Omeprazole | Omeprazole | 105 | 51 |
| Eliquis | Apixaban | 103 | 32 |
| Metformin Hcl Er | Metformin Hcl | 102 | 46 |
| Carvedilol | Carvedilol | 101 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 30 |
| Valsartan | Valsartan | 98 | 45 |
| Montelukast Sodium | Montelukast Sodium | 97 | 34 |
| Famotidine | Famotidine | 95 | 52 |
| Pregabalin | Pregabalin | 91 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 51 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 20 |
| Jardiance | Empagliflozin | 72 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 32 |
| Nystatin | Nystatin | 69 | 21 |
| Sertraline Hcl | Sertraline Hcl | 69 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 42 |
| Simvastatin | Simvastatin | 67 | 30 |
| Spironolactone | Spironolactone | 67 | 25 |
| Mirtazapine | Mirtazapine | 65 | 28 |
| Ondansetron Odt | Ondansetron | 65 | 50 |
| Synthroid | Levothyroxine Sodium | 65 | 26 |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Bupropion Xl | Bupropion Hcl | 63 | 11 |
| Lorazepam | Lorazepam | 63 | 26 |
| Azithromycin | Azithromycin | 61 | 49 |
| Potassium Chloride | Potassium Chloride | 61 | 29 |
| Trazodone Hcl | Trazodone Hcl | 59 | 21 |
| Donepezil Hcl | Donepezil Hcl | 57 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 26 |
| Meloxicam | Meloxicam | 54 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 48 |
| Diazepam | Diazepam | 48 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 17 |
| Fluconazole | Fluconazole | 46 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 14 |
| Ezetimibe | Ezetimibe | 44 | 17 |
| Fentanyl | Fentanyl | 44 | suppressed |
| Finasteride | Finasteride | 44 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 25 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | 12 |
| Entresto | Sacubitril/Valsartan | 41 | 11 |
| Naproxen | Naproxen | 41 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 23 |
| Farxiga | Dapagliflozin Propanediol | 39 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Cefdinir | Cefdinir | 38 | 35 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 13 |
| Celecoxib | Celecoxib | 32 | 13 |
| Glimepiride | Glimepiride | 31 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 30 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 26 |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Metolazone | Metolazone | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | 15 |
| Arformoterol Tartrate | Arformoterol Tartrate | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | 11 |
| Temazepam | Temazepam | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Glipizide Er | Glipizide | 20 | 11 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | 11 |
| Linzess | Linaclotide | 18 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Atenolol | Atenolol | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,429.41 · 136 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AUSTEDO XR, BREZTRI, CAPVAXIVE, COMIRNATY, ELIQUIS, FARXIGA, GEMTESA, IBSRELA, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SPRAVATO, SYNTHROID, UBRELVY, VOQUEZNA, VOWST, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error